MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13054-017-1769-z

Медицинская библиотека · Critical care (London, England) · 2017

Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.

De Pascale Gennaro, Martucci Gennaro, Montini Luca, Panarello Giovanna, Cutuli Salvatore Lucio, Di Carlo Daniele, Di Gravio Valentina, Di Stefano Roberta, Capitanio Guido, Vallecoccia Maria Sole, Polidori Piera, Spanu Teresa, Arcadipane Antonio, Antonelli Massimo

Контролируемое клиническое исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Recent reports have suggested the efficacy of a double carbapenem (DC) combination, including ertapenem, for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) infections. We aimed to evaluate the clinical impact of such a regimen in critically ill patients.

METHODS

This case-control (1:2), observational, two-center study involved critically ill adults with a microbiologically documented CR-Kp invasive infection treated with the DC regimen matched with those receiving a standard treatment (ST) (i.e., colistin, tigecycline, or gentamicin).

RESULTS

The primary end point was 28-day mortality. Secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Forty-eight patients treated with DC were matched with 96 controls. Occurrence of septic shock at infection and high procalcitonin levels were significantly more frequent in patients receiving DC treatment (p < 0.01). The 28-day mortality was significantly higher in patients receiving ST compared with the DC group (47.9% vs 29.2%, p = 0.04). Similarly, clinical cure and microbiological eradication were significantly higher when DC was used in patients infected with CR-Kp strains resistant to colistin (13/20 (65%) vs 10/32 (31.3%), p = 0.03 and 11/19 (57.9%) vs 7/27 (25.9%), p = 0.04, respectively). In the logistic regression and multivariate Cox-regression models, the DC regimen was associated with a reduction in 28-day mortality (OR 0.33, 95% CI 0.13-0.87 and OR 0.43, 95% CI 0.23-0.79, respectively).

CONCLUSIONS

Improved 28-day mortality was associated with the DC regimen compared with ST for severe CR-Kp infections. A randomized trial is needed to confirm these observational results.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03094494 . Registered 28 March 2017.

Для цитирования: De Pascale Gennaro, Martucci Gennaro, Montini Luca, Panarello Giovanna, Cutuli Salvatore Lucio, Di Carlo Daniele, Di Gravio Valentina, Di Stefano Roberta, Capitanio Guido, Vallecoccia Maria Sole, Polidori Piera, Spanu Teresa, Arcadipane Antonio, Antonelli Massimo. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.. Critical care (London, England). 2017. DOI: 10.1186/s13054-017-1769-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.